Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.
about
Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPVInfection transmission and chronic disease models in the study of infection-associated cancersPrevalence of human papillomavirus in head and neck cancers in European populations: a meta-analysisEurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines.Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.The cost of anal cancer in England: retrospective hospital data analysis and Markov model.Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy.Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in EuropeEconomic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analystsInclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission modelVaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine.Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females.Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?Governance of preventive Health Intervention and On time Verification of its Efficiency: the GIOVE Study.Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.Human papillomavirus type 58: the unique role in cervical cancers in East AsiaCost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model.Calibration of complex models through Bayesian evidence synthesis: a demonstration and tutorial.Primary prevention and vaccination for penile cancer.Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review.The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.Summary and Recommendations from the National Institute of Allergy and Infectious Diseases (NIAID) Workshop "Gonorrhea Vaccines: the Way Forward".Modeling preventative strategies against human papillomavirus-related disease in developed countriesCost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia.Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England.A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France.Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs.The cost of oropharyngeal cancer in England: A retrospective hospital data analysis.The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases.Achieving high and equitable coverage of adolescent HPV vaccine in Scotland.Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries.The health-economic studies of HPV vaccination in Southeast Asian countries: a systematic review.Quantitative benefit-risk assessment by MCDA of the quadrivalent HPV vaccine for preventing anal cancer in males.Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis.Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in MalaysiaPopulation-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based AnalysisSimultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis
P2860
Q26783973-E06B41B2-2B88-4CEE-8CA6-6CB8666EF097Q27011403-3A9E4223-3BDE-4591-A12C-3C811CA79655Q27027842-41A9D422-3FAF-4DDD-98F9-43A710C0F2F9Q30251868-90A97401-2961-4056-87F1-A9CC8760F8D9Q30573204-D2CFC434-2595-417D-A32C-D91253434B4EQ30866180-CA111EE5-F2FD-48B9-BDF3-FC7325272BFFQ33892348-B1AE98F0-E7CE-46B7-9C6A-95FD26DECA84Q34539349-E00179D9-882C-46E1-AC52-6C72805F646AQ34567701-4651D394-69C3-4DED-8D25-B5BD81E6A3AAQ34580293-AF95DFF2-4F78-4147-AC4E-F02C1E1BE4FCQ34852567-77D431E2-30CC-461C-B8F6-5D1242ACC8EAQ35005743-670E081C-4C05-4ED4-AD9A-6A619CDBDD08Q35092114-1ABDDAE5-C1E6-4A68-BFBF-5AE600BA43E1Q35779425-0C5A8294-83B6-4808-9B03-A1A97B32B8FFQ35838225-4E62128B-B3E1-4C2C-939A-B40B0BD35F91Q35991580-D05D75DD-09A8-4EA1-83A9-CA8D32FA05E8Q36150544-9CD8FD61-4D11-45D8-B1A2-D87C46A9518AQ36618532-62D2DF00-A5E1-4710-9E18-47606E0511C1Q36843345-C330E4AF-ADFB-4584-A5DD-B647393FB43EQ36847922-94FF44A5-8450-48D1-8498-F3BCBE2FA59DQ36914109-477A2647-A0EC-4AC3-878F-0D7933E3EC46Q37131038-D23787B2-74C9-42E9-BE28-DD023AA78D65Q37135272-93385C9D-23C8-4C2B-AAD3-921799CFEB79Q37163672-ADDCD0D5-F73E-4668-9936-24B4E2614671Q37198208-11FCAA73-D52A-4593-8ECE-BC320ACB1A1AQ37321084-8A90547E-74C6-4E27-96A7-DCAFC37A7E3EQ37503936-4A9D7F2C-B802-4D11-B78A-F6A1BE272D1CQ37521892-2F5BDB0C-ADC0-4545-88CF-697D14022038Q38255277-7FD9E65D-F320-48A3-A29F-0C56D6E57E9EQ38666893-7B98479A-F0BA-4BFC-A643-AFCB4542AF87Q38997255-9A84C5E9-96D7-48FB-81BD-413C2C8BD74EQ39359552-F2322430-D6E3-42AC-9206-5F21149FBE8BQ39438673-CB08F475-AB29-4526-A77D-DCF2E6E7E4BCQ39450074-545DD16F-529E-4F8A-BCB0-4EBBB38472C2Q40367033-CE9600D3-6E44-43A2-95EC-BA0119A5CE10Q42241908-A33EB630-8B40-4CEA-926A-7BA7CFAAE31FQ52727412-D0046B7A-73F9-4489-BF70-BD46721CABD6Q55540751-A6E201BB-683C-4591-A6E1-5CEB5EA7CD6EQ57089346-608C9E02-4B18-4C38-852F-E1932A8EF6B7Q58771818-ED1374E1-D429-4232-A699-7671EBAC9797
P2860
Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Comparing bivalent and quadriv ...... n based on transmission model.
@ast
Comparing bivalent and quadriv ...... n based on transmission model.
@en
type
label
Comparing bivalent and quadriv ...... n based on transmission model.
@ast
Comparing bivalent and quadriv ...... n based on transmission model.
@en
prefLabel
Comparing bivalent and quadriv ...... n based on transmission model.
@ast
Comparing bivalent and quadriv ...... n based on transmission model.
@en
P2093
P2860
P356
P1433
P1476
Comparing bivalent and quadriv ...... n based on transmission model.
@en
P2093
Owain Hughes
Ruth Chapman
Yoon Hong Choi
P2860
P356
10.1136/BMJ.D5775
P407
P50
P577
2011-09-27T00:00:00Z